HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

Circulation

Volumn 94, Issue 4, 1996, Pages 817-823

  Roy, Mary Louise ^a   Dumaine, Robert ^a   Brown, Arthur M ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

delayed rectifier; ketoconazole; oocytes; terfenadine

Indexed keywords

ANTIHISTAMINIC AGENT; MEMBRANE PROTEIN; PROTEIN HERG; TERFENADINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; HEART ATRIUM MUSCLE; NONHUMAN; OOCYTE; POTASSIUM CURRENT; PRIORITY JOURNAL; VOLTAGE CLAMP; XENOPUS;

EID: 0029761822     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.4.817     Document Type: Article

References (39)

1. 1992 National Prescription Audit. IMS America Ltd, Plymouth Meeting, Pa, 1992.
2. Honig PK, Wortham DC, Zamini K, Connor DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA. 1993;269: 1513-1518.
3. Davies AJ, Harinda V, McEwan A, Chose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J. 1989;298:325. Abstract.
4. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades des pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
5. Zimmerman M, Duruz H, Guinand O, Broccard O, Levy D, Lactis D, Bloch A. Torsades des pointes after treatment with terfenadine and ketoconazole. Eur Heart J. 1992;13:1002-1003.
6. Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med. 1994;160: 321-325.
7. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dis. 1994;22:849-857.
8. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF III, Guinosso PJ Jr, Lynch JJ Jr. Cardiac electrophysiological actions of the histamine HI-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995;73: 110-119.
9. Luo C, Rudy Y. A dynamic model of the cardiac ventricular action potential, I: simulations of ionic currents and concentration changes. Circ Res. 1994;74:1071-1096.
10. Martin BCL, Chinn K. Contribution of delayed rectifier and inward rectifier to repolarization of the action potential: pharmacologic separation. J Cardiovasc Pharmacol. 1992;19:830-837.
11. Sanguinetti MC, Jurkiewicz NK. Delayed rectifier potassium channels of cardiac muscle. In: Spooner PM, Brown AM, eds. Ion Channels in the Cardiovascular System: Function and Dysfunction. Armork, NY: Futura Publishing Co, Inc; 1994;121-143.
12. Noble D, Tsien RW. Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibers. J Physiol (Lond). 1969;200:205-231.
13. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195-215.
14. Balser JR, Bennet PB, Roden DM. Time-dependent outward current in guinea pig ventricular myocytes: gating kinetics of the delayed rectifier. J Gen Physiol. 1990;96:835-863.
15. Matsuura H, Ehara T, Imoto Y. An analysis of the delayed outward current in single ventricular cells of the guinea pig. Pflugers Arch. 1987;410:596-603.
16. + current similar to Kvl.5 cloned channel currents. Circ Res. 1993;73:1061-1076.
17. + channel current. Circ Res. 1993;73:210-216.
18. Woosley RL, Chen Y, Frieman JP, Gillis RA. Mechanisms of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
19. Crumb WJ, Wible BA, Arnold DJ, Payne JP, Brown AM. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol. 1995;47:181-190.
20. Berul CI, Morad M, Regulation of potassium channels by nonsedating antihistamines. Circulation. 1995;91:2220-2225.
21. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA. 1994;91:3438-3442.
22. Kr potassium channel. Cell. 1995;81:1-20.
23. Trudeau MC, Watmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995;269:92-95.
24. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
25. + channels. Science. 1994;264:844-847.
26. + channel cloned from human heart. J Pharmacol Exp Ther. 1993;44:1240-1245.
27. Clay JR, Ogbaghebriel A, Paquette T, Sasyniuk BI, Shrier A. A quantitative description of the E-4031-sensitive repolarization current in rabbit ventricular myocytes. Biophys J. 1995;69:1830-1837.
28. Roberds SL, Knoth KM, Po S, Blair TA, Bennett PB, Hartshorne RP, Snyders DJ, Tamkun MM. Molecular biology of the voltage-gated potassium channels of the cardiovascular system. J Cardiovasc Electrophysiol. 1993;4:68-80.
29. Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K*channel: open block by methanesulfonanilides. Circ Res. 1996; 78:499-503.
30. Ohler A, Amos GJ, Wettwer E, Ravens U. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedismal on action potential duration: no evidence for 'reverse use-dependent' block. Naunyn Schmiedebergs Arch Pharmacol. 1994;349:602-610.
31. Amos GJ, Wettwer E, Li Q, Himmel HM, Ravens U. Differences in outward currents of human atrial and ventricular myocytes. Circulation. 1994;4(suppl I):I-581. Abstract.
32. + channel cDNAs from human ventricle. FASEB J. 1991;5: 331-337.
33. Takumi T, Ohkubo H, Niakanishi S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science. 1988; 242:1042-1045.
34. Murai T, Kakizuka A, Takumi T, Ohkubo H, Nakanishi S. Molecular cloning and sequence analysis of human genomic DNA encoding a novel membrane protein which exhibits a slowly activating potassium channel activity. Biochem Biophys Res Commun. 1989;161: 176-181.
35. sK channel from neonatal rat heart and diethylstilbestrol-primed rat uterus. Proc Natl Acad Sci USA. 1990;87:2975-2979.
36. + current in ventricular myocytes of the guinea pig type. Circ Res. 1995;77:140-152.
37. Wong W, Pavlou HN, Birgersdotter UM, Hilleman DE, Mohiuddin SM, Roden DM. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol. 1992;69: 206-212.
38. Lang DG, Wang CM, Wenger TL. Terfenadine alters action potentials in isolated canine Purkinje fibers more than acrivastine. J Cardiovasc Pharmacol. 1993;22:438-442.
39. Sorkin EM, Heel RC. Terfenadine: a review of its pharmaco-dynamic properties and therapeutic efficacy. Drugs. 1985;29:34-56.